Singular Research Issues "Buy" Rating on Nymox With a 12-Month Target Price of $18.00
HASBROUCK HEIGHTS, N.J., July 2, 2012 (GLOBE NEWSWIRE) -- Singular Research has issued a new report on Nymox Pharmaceutical Corporation (NYMX) with a "Buy" rating and a 12 month target price of $18.00. The report was written by Gregory P. Garner, CFA, an equity research analyst for Singular Research. The report highlights the Company's Phase 2 trial for early stage prostate cancer, Phase 3 trial for BPH in Europe, and pivotal Phase 3 US trials for BPH close to full enrollment with continuing positive study safety data.
About Nymox: NX-1207 is a novel patented drug developed by Nymox. NX-1207 is currently in Phase 3 trials in the US for the treatment of benign prostatic hyperplasia (BPH) and in Phase 2 for localized prostate cancer. The drug is in Phase 3 for BPH in Europe where the Company's partner is Recordati S.p.A. NX-1207 has successfully completed a series of blinded controlled multi-center U.S. clinical trials where a single dose of NX-1207 has been found to produce symptomatic improvements for BPH about double that reported for currently approved drugs without causing the sexual or cardiovascular side effects associated with those drugs. NX-1207 is injected by a urologist in an office setting and involves little or no pain or discomfort. For more information about the NX-1207 Phase 3 clinical trials please go to www.clinicaltrials.gov or contact Nymox at email@example.com.
BPH treatment represents a growing market with more than 100 million men worldwide being estimated to suffer from BPH symptoms. The disorder is a common affliction of older men, affecting approximately half of men over age 50 and close to 90% of men by age 80, and is associated with growth in prostate size as men age. More information about Nymox is available at www.nymox.com , email: firstname.lastname@example.org, or 800-936-9669. Nymox made no payments to Singular Research for the research report.
About Singular Research: Singular Research aims to be the most trusted supplier of unbiased, performance-based research on small and micro-cap companies to fund managers. Analysts do not receive any form of direct compensation from companies under coverage. Analysts are compensated based on the accuracy of their research calls, not through paid for research by companies or potential deal flow. For more information visit www.singularresearch.com or contact Singular at 626-405-0242 or research@SingularResearch.com.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: For Further Information Contact: Roy Wolvin Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.comSource: Nymox Pharmaceutical Corporation 2012 GlobeNewswire, Inc.